ELDN
Eledon Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Eledon Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No other changes.
No other changes.
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
−4.32%
vs ±32.7% implied · ×0.13
shaded = implied · ▲▼ = realized
No trades yet today.
No trades yet today.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Eledon Pharmaceuticals, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Eledon Pharmaceuticals, Inc.'s 6 closest co-movers, none share that code.
| Manager | Value | % base | |
|---|---|---|---|
| BVF | $24.8M | 13.18% | 0.00% |
| BlackRockindex-like | $20.2M | 10.73% | +16.92% |
| Defilade | $13.9M | 7.38% | −1.09% |
| Vanguardindex-like | $13.5M | 7.15% | +3.77% |
| Goldman Sachs | $9.9M | 5.26% | +578.30% |
| Manager | Value | % base | |
|---|---|---|---|
| BVF | $24.8M | 13.18% | 0.00% |
| BlackRockindex-like | $20.2M | 10.73% | +16.92% |
| Defilade | $13.9M | 7.38% | −1.09% |
| Vanguardindex-like | $13.5M | 7.15% | +3.77% |
| Goldman Sachs | $9.9M | 5.26% | +578.30% |
Linked news
Tall tick = annual report · Source: EDGAR
Bull2
Bear2
Eledon Pharmaceuticals, Inc.
2.70
pre 2.78 +2.96%
Expected move
Inputsspot 2.70exp Nov 20ATM strike 2.5ATM straddle 0.88IV 200%